SCHEMBL23003226

SCHEMBL23003226

O=c1ccc2cnc(NC3CCNC3)nc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 2/20 0.56
▸ MAPK9 P45984 1/20 0.56
▸ MAPK10 P53779 1/20 0.56
▸ CDK7 P50613 6/20 0.46
▸ CCNH P51946 6/20 0.46
▸ MNAT1 P51948 6/20 0.46
▸ CDK2 P24941 5/20 0.46
▸ CCNA2 P20248 3/20 0.46
▸ CHEK1 O14757 1/20 0.46
▸ CCNK O75909 4/20 0.44
▸ CDK12 Q9NYV4 4/20 0.44
▸ BRD4 O60885 4/20 0.43
▸ ATAD2 Q6PL18 4/20 0.43
▸ SYK P43405 2/20 0.42
▸ KCNH2 Q12809 2/20 0.42
▸ MAPK3 P27361 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ MKNK1 Q9BUB5 1/20 0.41
▸ MKNK2 Q9HBH9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23003223 1.00 MAPK8 (0.56) MAPK8MAPK9MAPK10CDK7CCNH
SCHEMBL23003107 0.92 MAPK8 (0.56) MAPK8MAPK9MAPK10CDK7CCNH
SCHEMBL23003112 0.92 MAPK8 (0.56) MAPK8MAPK9MAPK10CDK7CCNH
SCHEMBL17910207 0.80 MAPK8 (0.66) MAPK8MAPK9MAPK10CDK7CCNH
SCHEMBL3052427 0.80 MAPK8 (0.60) MAPK8MAPK9MAPK10CDK7CCNH
SCHEMBL16802771 0.80 MAPK8 (0.66) MAPK8MAPK9MAPK10CDK7CCNH
SCHEMBL16802784 0.80 MAPK8 (0.63) MAPK8MAPK9MAPK10CDK7CCNH
SCHEMBL18148274 0.80 MAPK8 (0.63) MAPK8MAPK9MAPK10CDK7CCNH
SCHEMBL17910138 0.80 MAPK8 (0.56) MAPK8MAPK9MAPK10CDK7CCNH
SCHEMBL17910154 0.78 MAPK8 (0.60) MAPK8MAPK9MAPK10CDK7CCNH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11447493-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. 2022-09-20 — — US disclosed
EP-3787629-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES Kinnate Biopharma Inc. (US) 2021-03-10 — — EP disclosed
US-20210053969-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210053969-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK2, CCNK, CDK1 MAPK8 336/4885MAPK9 253/4885MAPK10 401/4885
US-11447493-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 MAPK8 336/4885MAPK9 253/4885MAPK10 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback